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ABSTRACT
Background: COVID-19 has been associated with cases of severe respiratory illness, admissions to intensive therapy
units (ITUs), and high mortality rates.
Objectives: The aim of the present study was to examine the relation between computed tomography- body
composition (CT-BC) measurements, systemic inflammation, and clinical outcomes in those with COVID-19.
Methods: Patients who presented to our institution between March 17 and May 1, 2020, with a positive PCR
test for COVID-19 or characteristic radiological changes, were assessed for inclusion. Data collected included general
demographic details, clinicopathological variables, poGPS, NLR , CT-BC measurements, and clinical outcomes including
ITU admission and 30-d mortality, of those admitted.
Results: Sixty-three patients met the study inclusion criteria. Forty-two patients (67%) were aged ≥70 y, 30 (47.6%)
were male and 34.9% ( n = 22) had a poGPS ≥1. ITU admission was significantly associated with a high VFA ( P < 0.05).
Thirty-day mortality was associated with high VFA (P < 0.05) and low SMI (P < 0.05).
Conclusions: Sarcopenia in the presence of obesity was associated with clinical outcomes including greater 30-d
mortality. J Nutr 2021;00:1–9.
Keywords: body composition, obesity, sarcopenia, CT, COVID-19
Introduction
The WHO declared the outbreak of novel coronavirus 19
(COVID-19) a global pandemic on March 11, 2020 (1).
Despite an expansion in resources for testing and contact
tracing, hospital admissions and death rates within the United
Kingdom remained high (2). Since first identified, COVID-19
has been associated with cases of severe respiratory illness, often
requiring hospitalization and in some cases admission to an
intensive therapy unit (ITU), as well as high mortality rates (3).
With the potential for health services to become overwhelmed
due to finite resources such as ventilators and level 3 ITU beds
available and staffed, factors that aid in prognostication are
essential to triage those admitted with COVID-19. This could
provide an invaluable insight in the fight against the current
global pandemic.
A marked systemic inflammatory response has been identi-
fied as one of the signs of severe COVID-19 (4). Recent studies
have shown that severe systemic inflammation is associated
with mortality in those with COVID-19, suggesting that it can
have a role in determining prognosis. Furthermore, obesity,
as measured by BMI (5) and visceral fat area (VFA) (6, 7)
derived from computed tomography (CT) image analysis, has
been reported to have a detrimental impact on clinical outcomes
in those with COVID-19. The relation between CT-derived
measures of body composition including low skeletal muscle
mass and density, systemic inflammation, and outcomes in those
with cancer have previously been reported (8, 9). However, to
date, there have been no studies exploring the relation between
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FIGURE 1 Flow diagram of included patients with COVID-19 and satisfactory CT imaging. AP, abdomen and pelvis; COVID-19, coronavirus
disease; CT, computed tomography; Dx, diagnosis; TAP, thorax, abdomen, and pelvis.
systemic inflammation, CT-derived body composition (CT-BC)
measurements, and clinical outcomes in those with COVID-19.
Therefore, the aim of the present study was to examine the
relation between CT-BC measurements, systemic inflammatory
status, and clinical outcomes in those with COVID-19.
Methods
Data were collected on patients who attended the Emergency De-
partment (ED) and Acute Assessment Unit (AAU) at Glasgow Royal
Infirmary (GRI), Glasgow, United Kingdom, during the initial 7-wk
period of the COVID-19 pandemic in Glasgow city (March 17, 2020
to May 1, 2020). GRI is a university teaching hospital, serving an urban
population with a high burden of socioeconomic deprivation. In line
with UK National Health Service (NHS) policy, this study was approved
by the NHS Greater Glasgow and Clyde Caldicott guardian. The study
protocol (GN20AE307) was approved by the North West England—
Preston research ethics committee (20/NW/0336) and registered with
clinicaltrials.gov (NCT04484545).
Patients displaying clinical signs or symptoms consistent with
possible COVID-19 (as defined by Health Protection Scotland) (10), at
the time of presentation to the ED and AAU, were assessed for inclusion
in the study. Patients were then further analyzed to identify those with
either a positive PCR test or radiological changes characteristic of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
reported on chest X-ray or CT thorax, by a board-certified radiologist.
Finally, patients with confirmed COVID-19 were then assessed to
identify those who had CT imaging within 3 mo of the diagnosis
(see Figure 1). Eligible CT imaging required cross-sectional scanning
at the level of the third lumbar vertebra. Patients whose scans were
taken outwith this period were excluded from the study. Furthermore,
scans with significant movement artefact or missing region of interest
were not considered for inclusion.
Routine demographic details, clinical observations, hematological
and biochemical laboratory results, as well as clinical outcome data
were recorded. Age, sex, ethnicity, BMI, and diagnostic modality
confirming COVID-19 as well as date of diagnosis were minimal
inclusion criteria. Age categories were grouped to <70 y or ≥70 y. Social
deprivation was defined by the Scottish Indices of Multiple Deprivation
2019 based on individuals’ home postcodes. Ethnicity was classified
as white or other ethnic group. Admission serum C-reactive protein
(CRP), albumin, and differential blood cell counts were categorized
using local reference intervals. Neutrophil:lymphocyte ratio (NLR) (11)
and the perioperative Glasgow Prognostic Score (poGPS) (12) were used
to assess systemic inflammation. For this study, thresholds of NLR <3,
3–5, >5 were chosen and categorized as “mild,” “moderate,” and
“severe” systemic inflammatory response, respectively. poGPS values
were grouped into “noninflamed”(i.e., poGPS = 0) and “inflamed”(i.e.,
poGPS = 1 or 2) cohorts. Primary outcomes measured were intensive
care admission and mortality within 30 d of diagnosis with COVID-19.
Body composition analysis
Each CT image was individually analyzed using ImageJ—a free to
download, Java-based program developed by NIH (NIH ImageJ version
1.47; http://rsbweb.nih.gov/ij/) shown to provide reliable measurements
(13). Body composition measurements derived from the CT image
slice at L3 included total fat area (TFA), visceral fat area (VFA), and
skeletal muscle area (SMA). Attenuation thresholds were from −190
to +30 Hounsfield units (HU) for fat and −29 to +150 HU for
muscle. The TFA was quantified by depicting the outer contours of
the abdominal wall, compared with the inner contour of the psoas
and abdominal wall muscles for VFA. Similarly, SMA was measured by
manually delineating muscle areas including the quadratus lumborum,
psoas, rectus abdominus, and erector spinae muscles, and the internal
transverse and external oblique muscle groups. Skeletal muscle
radiodensity (SMD) was calculated (in Hounsfield units) as the mean
of the measured muscle area used to calculate SMI. Subcutaneous fat
area (SFA) was calculated by subtraction of the VFA from TFA. SFA and
SMA measurements were then normalized by division of the patient’s
height in meters squared to generate a subcutaneous fat index (SFI:
centimeters squared/meters squared) and skeletal muscle index (SMI:
centimeters squared/meters squared). These indices were then compared
with established thresholds for body composition status (see Table 1).
Statistical analysis
Demographic data, CT-BC measurements, poGPS, and NLR were
presented as categorical variables. Categorical variables were analyzed
using χ2 test for linear-by-linear association.
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TABLE 1 Results of body composition analysis of patients with COVID-19 determined from CT1
Body composition measurement Frequency, n (%)
Obesity
High SFI (14): males >50.0 cm2/m2; females >42.0 cm2/m2 No: 16 (25.4); yes: 47 (74.6)
Visceral obesity (15, 16): VFA: males >160 cm2; females >80 cm2 No: 21 (33.3); yes: 42 (66.7)
Sarcopenia
SMI (15):
Males: BMI <25 kg/m2 and SMI <43 cm2/m2, or BMI ≥25 and SMI <53 cm2/m2
Females: BMI <25 and SMI <41 cm2/m2, or BMI ≥25 and SMI <41 cm2/m2
No: 24 (38.1); yes: 39 (61.9)
Myosteatosis
SMD (15): BMI <25 and SMD <41 HU, or BMI ≥25 and SMD <33 HU No: 12 (19.0); yes: 51 (81.0)
1COVID-19, coronavirus disease; CT, computed tomography; HU, Hounsfield units; SFI, subcutaneous fat index; SMD, skeletal
muscle radiodensity; SMI, skeletal muscle index; VFA, visceral fat area.
Missing data were excluded from analysis on a variable-by-
variable basis. Two-tailed P values <0.05 were considered statistically
significant. Statistical analysis was performed using SPSS software
version 25.0 (SPSS Inc.).
Results
Of the 224 patients admitted to GRI during the study period,
63 met the study inclusion criteria. The clinicopathological
characteristics at presentation are shown in Table 2. Forty-
two patients (67%) were aged ≥70 y. Thirty (48%) participants
were male. The majority of patients were of white, Scottish
ethnicity (94%). With the exception of hypertension, which
was present in 34 (53%) individuals included, the majority
of patients had no history of comorbid disease—heart failure
(13%), type 2 diabetes (28%), liver disease (10%), chronic
renal failure (18%), asthma (21%), and chronic obstructive
pulmonary disease (22%). Of those included, 11 (18%) patients
had active cancer. Of those admitted, 16% (n = 10) were current
smokers, with 28 (44%) patients reporting a past history of
smoking.
The median BMI was 26.5 kg/m2, with 49% (n = 31)
of patients having a BMI ≥25, and 24% (n = 15) having a
BMI ≥30. A severe systemic inflammatory response (CRP ≥80
g/L) was present in almost half of individuals studied (49%)
(n = 31), and a very severe systemic inflammatory response
(CRP ≥150 g/L) was present in 14 (22%). A serum albumin
<35 mg/L was present in 84% (n = 53) of individuals. Seventeen
(27%) patients had a poGPS score of 1, and 5 (8%) had a
poGPS of 2. An NLR of 3–5 was reported in 22% (n = 14)
of individuals studied, with 39 (62%) having an NLR >5,
indicating moderate and severe inflammation, respectively.
Of the patients with imaging deemed to be of sufficient,
analyzable standard for inclusion within the study, 48 (76%)
had a CT thorax, abdomen, and pelvis, with 24% (n = 13)
having a CT abdomen and pelvis only. CT-BC measurements
included were VFA, SFI, SMI, and SMD using predefined
thresholds. CT-BC analysis results are shown in Table 1. A
high VFA was present in 67% (n = 42) of patients. VFA
was significantly associated with BMI (P < 0.01), smoking
status (P < 0.01), active cancer (P < 0.01), ITU admission
(P < 0.05), and 30-d mortality (P < 0.01; Table 3). A high SFI
was present in a greater number of patients: 75% (n = 47). SFI
was associated with gender (P ≤ 0.05), age (P < 0.01), BMI
(P < 0.01), chronic renal failure (P < 0.05), asthma (P < 0.05),
and active cancer (P < 0.05; Table 4). SMI and SMD were
assessed using thresholds defined by Martin et al. (15). A low
SMI was present in 62% (n = 39) of patients, and a low
SMD in 81% (n = 51). Low SMI was associated with BMI
(P < 0.01) and 30-d mortality (P < 0.05; Table 5). A low SMD
was associated with age (P < 0.05; Table 6).
Of the patients included, 3 (5%) had an ITU admission.
Two patients were admitted directly to ITU from the ED, with
1 requiring escalation to a level 3 bed from ward-level care
during admission. ITU admission was significantly associated
with a high VFA (P < 0.05; Table 3). Thirty-day mortality was
associated with high VFA (P < 0.05) and low SMI (P < 0.05;
see Tables 3 and 5, respectively).
Discussion
To our knowledge, this is the first study to explore the relation
between CT-BC measurements, systemic inflammation, and
outcomes in patients with COVID-19. The patients included
were mainly elderly, were of white ethnicity, were systemically
inflamed, overweight with subcutaneous and visceral obesity,
and had sarcopenia using standard thresholds. Furthermore,
sarcopenia in the presence of obesity was associated with
clinical outcomes including greater 30-d mortality. Therefore, it
would appear that body composition could have an important
role in predicting clinical outcome in patients presenting
with COVID-19. Further large-scale studies are warranted to
establish the prognostic role of body composition in these
patients.
Numerous studies have suggested that obesity, as measured
by BMI, is associated with poorer outcomes in patients with
COVID-19 (5, 17). However, BMI reflects both fat and muscle
mass in the body and therefore it is not clear whether such
increased risk is due to high fat mass, low muscle mass, or both.
In the present study visceral obesity appeared to be associated
with a lower 30-d mortality whereas sarcopenia was associated
with a higher 30-d mortality. The basis of this divergence of
body composition components and clinical outcome is not clear.
However, a low muscle mass against a background of an acute
(18) or chronic inflammatory state has long been recognized to
be associated with poor clinical outcomes (19). Irrespective, it
will be important to carry out further body composition studies
in patients with COVID-19 .
Sarcopenia has been shown to be prevalent in the elderly
population as well as those with cancer (20, 21). The prevalence
of a low SMI in this COVID-19 cohort was ∼50% when those
with cancer were excluded. If we compare this with cohorts
of patients with curative colorectal and advanced lung cancer,
similar levels of prevalence of a low SMI are observed (8,
9). This would suggest that sarcopenia is endemic and not
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TABLE 2 Patient characteristics1
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1COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT,
computed tomography; ITU, intensive therapy or care unit; NLR,
neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow Prognostic Score; T2DM,
type 2 diabetes mellitus.
exclusive to those with COVID-19. This brings into question
of how to mitigate the inflammatory effects of COVID-19 in
such patients. Clearly, moderation of the systemic inflammatory
response could be important, and indeed randomized controlled
trials have shown the value of anti-inflammatory agents (22).
From the present results it can be speculated that COVID-19
patients with sarcopenia will benefit most from such therapeutic
agents.
Systemic inflammation has been shown to be associated with
poor outcomes in patients with COVID-19 (23). In addition,
several studies have shown the negative impact of an elevated
NLR on those with COVID-19 (24, 25). The poGPS is a
validated score that is independently associated with infective
complications and 30-d mortality in patients undergoing
surgery (12). This score was chosen due to the significant degree
of inflammation exhibited by those with COVID-19. A similar
prevalence of systemic inflammation, as measured by CRP ≥80,
poGPS ≥1, and NLR to >5, was observed in the present cohort
(49%, 36%, and 62%, respectively), and across the entire
cohort from which the patients in this study were identified
(51%, 25%, and 55%, respectively) (23). Furthermore, when
compared with COVID-19 cohorts from further afield, such as
the Far East, such systemic inflammation was also prevalent
(26). Therefore, activation of the host systemic inflammatory
response is a consistent feature of this disease. From the present
results it may be speculated that the prognostic value and
treatment of the systemic inflammatory response will be greatest
in those COVID-19 patients with sarcopenia.
There are a number of limitations of this present study.
Importantly, this study is a single-center study with a small
sample size and therefore subject to sample bias. Although
the present study has a small sample size, it is important to
highlight that not all patients with COVID-19 undergo routine
CT imaging in the United Kingdom. Within the literature
there is a single study with a larger cohort than ours (27).
However, they used a nonstandardized methodology for the
calculation of SMI (27). Two other smaller studies assessed
the relation between VFA and clinical outcomes in those with
COVID-19 (6, 7). To our knowledge, the present study has
the largest cohort to date exploring the relation between CT
body composition measurements, systemic inflammation, and
clinical outcomes in patients with COVID-19. Therefore, the
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Male 30 (47.6) 12 (57.1) 18 (42.9)
Female 33 (52.4) 9 (42.9) 24 (57.1)
Age, y 0.571
<70 21 (33.3) 6 (28.6) 15 (35.7)
≥70 42 (66.7) 15 (71.4) 27 (64.3)
Ethnicity 0.715
White 59 (93.7) 20 (95.2) 39 (92.9)
Other 4 (6.3) 1 (4.8) 3 (7.1)
BMI, kg/m2 0.003
25–29 16 (51.6) 3 (14.3) 13 (31.0)
≥30 15 (48.4) 1 (4.8) 14 (33.3)
Smoking status 0.009
Current 10 (15.9) 7 (33.3) 3 (7.1)
Ex 28 (44.4) 10 (47.6) 18 (42.9)
Never 25 (39.7) 4 (19.0) 21 (50.0)
Alcohol excess Hx. 0.241
Yes 11 (17.5) 2 (9.5) 9 (21.4)
No 52 (82.5) 19 (90.5) 33 (78.6)
Clinical frailty 0.356
Yes 45 (71.4) 17 (81.0) 28 (70.0)
No 16 (25.4) 4 (19.0) 12 (30.0)
Liver disease
Yes 6 (9.5) 1 (4.8) 5 (11.9)
No 57 (90.5) 20 (95.2) 37 (88.1) 0.363
Hypertension 0.721
Yes 34 (53.1) 12 (57.1) 22 (52.4)
No 29 (45.3) 9 (42.9) 20 (47.6)
Heart failure 0.539
Yes 8 (12.7) 2 (9.5) 6 (14.3)
No 55 (87.3) 19 (90.5) 36 (85.7)
T2DM 0.076
Yes 18 (28.1) 3 (14.3) 15 (35.7)
No 45 (70.3) 18 (85.7) 27 (64.3)
Chronic renal failure 0.348
Yes 11 (17.5) 5 (23.8) 6 (14.3)
No 52 (82.5) 16 (76.2) 36 (85.7)
Asthma 0.123
Yes 13 (20.6) 2 (9.5) 11 (26.2)
No 50 (79.4) 19 (90.5) 31 (73.8)
COPD 0.391
Yes 14 (22.2) 6 (28.6) 8 (19.0)
No 49 (77.8) 15 (71.4) 34 (81.0)
Active cancer 0.019
Yes 11 (17.5) 7 (33.3) 4 (9.5)
No 52 (82.5) 14 (66.7) 38 (90.5)
CRP, mg/L 0.188
≥10 52 (82.5) 6 (28.6) 21 (42.9)
≥80 31 (49.2) 7 (33.3) 7 (22.2)
≥150 14 (22.2) 8 (38.1) 14 (33.3)
Albumin, g/L 0.271
<25 13 (20.6) 6 (28.6) 7 (16.7)
≥25 50 (79.4) 15 (71.4) 35 (83.3)
NLR 0.132
<3 10 (15.6) 1 (4.8) 9 (21.4)
3–5 12 (18.8) 3 (14.3) 9 (21.4)
>5 41 (64.1) 17 (81.0) 24 (57.1)
poGPS 0.350
0 41 (65.1) 12 (57.1) 29 (69.0)
1–2 22 (34.9) 9 (42.9) 13 (31.0)
ITU admission 0.012
Yes 3 (4.8) 3 (14.3) 0 (0)
No 60 (95.2) 18 (85.7) 42 (100)
30-d mortality 0.002
Yes 11 (17.5) 8 (38.1) 3 (7.1)
No 52 (82.5) 13 (61.9) 39 (92.9)
1Values are n (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein;
Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow
Prognostic Score; T2DM, type 2 diabetes mellitus; VFA, visceral fat area.
2High VFA defined as >160 cm2 for males and >80 cm2 for females.
3P value is from χ2 analysis.
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Male 30 (47.6) 11 (68.8) 19 (40.4)
Female 33 (52.4) 5 (31.3) 28 (59.6)
Age, y 0.008
<70 21 (33.3) 1 (6.2) 20 (42.6)
≥70 42 (66.7) 15 (93.8) 27 (57.4)
Ethnicity 0.228
White 59 (93.7) 16 (100) 43 (91.5)
Other 4 (6.3) 0 (0) 4 (8.5)
BMI, kg/m2 0.002
25–29 16 (51.6) 2 (12.5) 14 (29.8)
≥30 15 (48.4) 0 (0) 15 (31.9)
Smoking status 0.113
Current 10 (15.9) 5 (31.3) 5 (10.6)
Ex 28 (44.4) 7 (43.8) 21 (44.7)
Never 25 (39.7) 4 (25.0) 21 (44.7)
Alcohol excess Hx. 0.171
Yes 11 (17.5) 1 (6.3) 10 (21.3)
No 52 (82.5) 15 (93.8) 37 (78.7)
Clinical frailty 0.146
Yes 45 (71.4) 14 (87.5) 31 (68.9)
No 16 (25.4) 2 (12.5) 14 (31.1)
Liver disease 0.133
Yes 6 (9.5) 0 (0) 6 (12.8)
No 57 (90.5) 16 (100) 41 (87.2)
Hypertension 0.832
Yes 34 (53.1) 9 (56.3) 25 (53.2)
No 29 (45.3) 7 (43.8) 22 (46.8)
Heart failure 0.087
Yes 8 (12.7) 4 (25.0) 4 (8.5)
No 55 (87.3) 12 (75.0) 43 (91.5)
T2DM 0.314
Yes 18 (28.1) 3 (18.8) 15 (31.9)
No 45 (70.3) 13 (81.3) 32 (68.1)
Chronic renal failure 0.014
Yes 11 (17.5) 6 (37.5) 5 (10.6)
No 52 (82.5) 10 (62.5) 42 (89.4)
Asthma 0.018
Yes 13 (20.6) 0 (0) 13 (27.7)
No 50 (79.4) 16 (100) 34 (72.3)
COPD 0.757
Yes 14 (22.2) 4 (25.0) 10 (21.3)
No 49 (77.8) 12 (75.0) 37 (78.7)
Active cancer 0.014
Yes 11 (17.5) 6 (37.5) 5 (10.6)
No 52 (82.5) 10 (62.5) 42 (89.4)
CRP, mg/L 0.498
≥10 52 (82.5) 7 (43.8) 15 (38.5)
≥80 31 (49.2) 5 (31.3) 10 (25.6)
≥150 14 (22.2) 4 (25.0) 14 (35.9)
Albumin, g/L 0.829
<25 13 (20.6) 3 (18.8) 10 (21.3)
≥25 50 (79.4) 13 (81.3) 37 (78.7)
NLR 0.905
<3 10 (15.6) 2 (12.5) 8 (17.0)
3–5 12 (18.8) 3 (18.8) 9 (19.1)
>5 41 (64.1) 11 (68.8) 30 (63.8)
poGPS 0.116
0 41 (65.1) 13 (81.3) 28 (59.6)
1–2 22 (34.9) 3 (18.8) 19 (40.4)
ITU admission 0.746
Yes 3 (4.8) 1 (6.2) 2 (4.3)
No 60 (95.2) 15 (93.8) 45 (95.7)
30-dmortality 0.093
Yes 11 (17.5) 5 (31.3) 6 (12.8)
No 52 (82.5) 11 (68.8) 41 (87.2)
1Values are n (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein;
Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow
Prognostic Score; SFI, subcutaneous fat index; T2DM, type 2 diabetes mellitus.
2High SFI defined as >50.0 cm2/m2 for males and >42.0 cm2/m2 for females.
3P value is from χ2 analysis.









 user on 08 July 2021












Male 30 (47.6) 11 (45.8) 19 (48.7)
Female 33 (52.4) 13 (54.2) 20 (51.3)
Age, y 0.271
<70 21 (33.3) 10 (41.7) 11 (28.2)
≥70 42 (66.7) 14 (58.3) 28 (71.8)
Ethnicity 0.577
White 59 (93.7) 23 (95.8) 36 (92.3)
Other 4 (6.3) 1 (4.2) 3 (7.7)
BMI, kg/m2 0.003
25–29 16 (51.6) 3 (14.3) 13 (31.0)
≥30 15 (48.4) 1 (4.8) 14 (33.3)
Smoking status 0.182
Current 10 (15.9) 3 (12.5) 7 (17.9)
Ex 28 (44.4) 8 (33.3) 20 (51.3)
Never 25 (39.7) 13 (54.2) 12 (30.8)
Alcohol excess Hx. 0.216
Yes 11 (17.5) 6 (25.0) 5 (12.8)
No 52 (82.5) 18 (75.0) 34 (87.2)
Clinical frailty 0.177
Yes 45 (71.4) 14 (63.6) 31 (79.5)
No 16 (25.4) 8 (36.4) 8 (20.5)
Liver disease 0.130
Yes 6 (9.5) 4 (16.7) 2 (5.1)
No 57 (90.5) 20 (83.3) 37 (94.9)
Hypertension 0.980
Yes 34 (53.1) 13 (54.2) 21 (53.8)
No 29 (45.3) 11 (45.8) 18 (46.2)
Heart failure 0.128
Yes 8 (12.7) 5 (20.8) 3 (7.7)
No 55 (87.3) 19 (79.2) 36 (92.3)
T2DM 0.623
Yes 18 (28.1) 6 (25.0) 12 (30.8)
No 45 (70.3) 18 (75.0) 27 (69.2)
Chronic renal failure 0.216
Yes 11 (17.5) 6 (25.0) 11 (17.5)
No 52 (82.5) 18 (75.0) 52 (82.5)
Asthma 0.976
Yes 13 (20.6) 5 (20.8) 8 (20.5)
No 50 (79.4) 19 (79.2) 31 (79.5)
COPD 0.677
Yes 14 (22.2) 6 (25.0) 8 (20.5)
No 49 (77.8) 18 (75.0) 31 (79.5)
Active cancer 0.896
Yes 11 (17.5) 4 (16.7) 7 (17.9)
No 52 (82.5) 20 (83.3) 32 (82.1)
CRP, mg/L 0.598
≥10 52 (82.5) 12 (50.0) 15 (38.5)
≥80 31 (49.2) 4 (16.7) 10 (25.6)
≥150 14 (22.2) 8 (33.3) 14 (35.9)
Albumin, g/L 0.541
<25 13 (20.6) 4 (16.7) 9 (23.1)
≥25 50 (79.4) 20 (83.3) 30 (76.9)
NLR 0.245
<3 10 (15.6) 6 (25.0 4 (10.3)
3–5 12 (18.8) 5 (20.8) 7 (17.9)
>5 41 (64.1) 13 (54.2) 28 (68.3)
poGPS 0.452
0 41 (65.1) 7 (29.2) 15 (38.5)
1–2 22 (34.9) 17 (70.8) 24 (61.5)
ITU admission 0.862
Yes 3 (4.8) 1 (4.2) 2 (5.1)
No 60 (95.2) 23 (95.8) 37 (94.9)
30-d mortality 0.029
Yes 11 (17.5) 1 (4.2) 10 (25.6)
No 52 (82.5) 23 (95.8) 29 (74.4)
1Values are n (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein;
Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow
Prognostic Score; SMI, skeletal muscle index; T2DM, type 2 diabetes mellitus.
2Low SMI defined as BMI <25 kg/m2 and SMI <43 cm2/m2, or BMI ≥25 and SMI <53 cm2/m2 for males; and BMI <25
and SMI <41 cm2/m2, or BMI ≥25 and SMI <41 cm2/m2 for females.
3P value is from χ2 analysis.
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Male 30 (47.6) 9 (75.0) 21 (41.2)
Female 33 (52.4) 3 (25.0) 30 (58.8)
Age, y 0.173
<70 21 (33.3) 6 (50.0) 15 (29.4)
≥70 42 (66.7) 6 (50.0) 36 (70.6)
Ethnicity 0.316
White 59 (93.7) 12 (100) 47 (92.2)
Other 4 (6.3) 0 (0) 4 (7.8)
BMI, kg/m2 <0.001
25–29 16 (51.6) 10 (83.3) 6 (11.8)
≥30 15 (48.4) 2 (16.7) 13 (25.5)
Smoking status 0.878
Current 10 (15.9) 2 (16.7) 8 (15.7)
Ex 28 (44.4) 6 (50.0) 22 (43.1)
Never 25 (39.7) 4 (33.3) 21 (41.2)
Alcohol excess Hx. 0.107
Yes 11 (17.5) 4 (33.3) 7 (13.7)
No 52 (82.5) 8 (66.7) 44 (86.3)
Clinical frailty 0.175
Yes 45 (71.4) 7 (58.3) 38 (77.6)
No 16 (25.4) 5 (41.7) 11 (22.4)
Liver disease 0.876
Yes 6 (9.5) 1 (8.3) 5 (9.8)
No 57 (90.5) 11 (91.7) 46 (90.2)
Hypertension 0.759
Yes 34 (53.1) 6 (50.0) 28 (54.9)
No 29 (45.3) 6 (50.0) 23 (45.1)
Heart failure 0.614
Yes 8 (12.7) 1 (8.3) 7 (13.7)
No 55 (87.3) 11 (91.7) 44 (86.3)
T2DM 0.685
Yes 18 (28.1) 4 (33.3) 14 (27.5)
No 45 (70.3) 8 (66.7) 37 (72.5)
Chronic renal failure 0.355
Yes 11 (17.5) 1 (8.3) 10 (19.6)
No 52 (82.5) 11 (91.7) 41 (80.4)
Asthma 0.242
Yes 13 (20.6) 1 (8.3) 12 (23.5)
No 50 (79.4) 11 (91.7) 39 (76.5)
COPD 0.607
Yes 14 (22.2) 2 (16.7) 12 (23.5)
No 49 (77.8) 10 (83.3) 39 (76.5)
Active cancer 0.355
Yes 11 (17.5) 1 (8.3) 10 (19.6)
No 52 (82.5) 11 (91.7) 41 (80.4)
CRP, mg/L 0.817
≥10 52 (82.5) 5 (41.7) 22 (43.1)
≥80 31 (49.2) 2 (16.7) 12 (23.5)
≥150 14 (22.2) 5 (41.7) 17 (33.3)
Albumin, g/L 0.242
<25 13 (20.6) 1 (8.3) 12 (23.5)
≥25 50 (79.4) 11 (91.7) 39 (76.5)
NLR 0.456
<3 10 (15.6) 3 (25.0) 7 (13.7)
3–5 12 (18.8) 3 (25.0) 9 (17.6)
>5 41 (64.1) 6 (50.0) 35 (68.6)
poGPS 0.898
0 41 (65.1) 8 (66.7) 18 (35.3)
1–2 22 (34.9) 4 (33.3) 33 (64.7)
ITU admission 0.518
Yes 3 (4.8) 1 (8.3) 2 (3.9)
No 60 (95.2) 11 (91.7) 49 (96.1)
30-dmortality 0.355
Yes 11 (17.5) 1 (8.3) 11 (17.5)
No 52 (82.5) 11 (91.7) 52 (82.5)
1Values are n (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein;
HU, Hounsfield unit; Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS,
perioperative Glasgow Prognostic Score; SMD, skeletal muscle radiodensity; T2DM, type 2 diabetes mellitus.
2Low SMD defined as BMI <25 kg/m2 and SMD <41 HU, or BMI ≥25 and SMD <33 HU for both sexes.
3P value is from χ2 analysis.
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present cohort provides a novel insight into the relation of body
composition and systemic inflammation in those with COVID-
19. Furthermore, although it is possible that the relation of
SMI with mortality was an age-related factor, when patients
older than 65 y were excluded from the univariate analysis,
the association between SMI and 30-d mortality remained
significant (n = 21, P = 0.028). A larger cohort of patients will
be required to address this point in detail.
In summary, sarcopenia in the presence of obesity was
associated with clinical outcomes including greater 30-d
mortality. Therefore, it would appear that body composition
can have an important role in predicting clinical outcome in
patients presenting with COVID-19.
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